GeoVax Labs (GOVX) Competitors $0.72 +0.00 (+0.61%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. PEPG, JSPR, CVM, RNXT, XCUR, NBRV, ACRV, CGTX, LTRN, and ELYMShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include PepGen (PEPG), Jasper Therapeutics (JSPR), CEL-SCI (CVM), RenovoRx (RNXT), Exicure (XCUR), Nabriva Therapeutics (NBRV), Acrivon Therapeutics (ACRV), Cognition Therapeutics (CGTX), Lantern Pharma (LTRN), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors PepGen Jasper Therapeutics CEL-SCI RenovoRx Exicure Nabriva Therapeutics Acrivon Therapeutics Cognition Therapeutics Lantern Pharma Eliem Therapeutics GeoVax Labs (NASDAQ:GOVX) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Do analysts rate GOVX or PEPG? GeoVax Labs presently has a consensus price target of $8.88, indicating a potential upside of 1,124.64%. PepGen has a consensus price target of $7.67, indicating a potential upside of 480.81%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer GOVX or PEPG? In the previous week, PepGen had 14 more articles in the media than GeoVax Labs. MarketBeat recorded 26 mentions for PepGen and 12 mentions for GeoVax Labs. PepGen's average media sentiment score of 0.04 beat GeoVax Labs' score of 0.04 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 2 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in GOVX or PEPG? 6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 1.2% of GeoVax Labs shares are owned by insiders. Comparatively, 5.2% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, GOVX or PEPG? GeoVax Labs has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.95M2.92-$24.99M-$2.01-0.36PepGenN/AN/A-$89.98M-$3.13-0.42 Which has more risk & volatility, GOVX or PEPG? GeoVax Labs has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Is GOVX or PEPG more profitable? PepGen has a net margin of 0.00% compared to GeoVax Labs' net margin of -403.88%. PepGen's return on equity of -81.26% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax Labs-403.88% -408.80% -279.89% PepGen N/A -81.26%-63.65% SummaryGeoVax Labs beats PepGen on 8 of the 15 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.47M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-0.3617.6228.6723.80Price / Sales2.92269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book4.038.508.275.55Net Income-$24.99M-$55.06M$3.24B$259.03M7 Day Performance-8.27%-3.98%-3.63%-4.56%1 Month Performance51.99%9.59%4.40%4.49%1 Year Performance-62.26%6.72%25.97%18.05% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs2.4265 of 5 stars$0.72+0.6%$8.88+1,124.6%-65.7%$11.47M$3.95M-0.3610Earnings ReportAnalyst ForecastAnalyst RevisionPEPGPepGen2.6438 of 5 stars$1.43-1.4%$7.67+436.1%-86.9%$46.79MN/A-0.4630Gap DownJSPRJasper Therapeutics2.6846 of 5 stars$3.10-1.6%$29.75+859.7%-83.4%$46.56MN/A-0.5920CVMCEL-SCI1.1884 of 5 stars$8.66+5.6%N/A-72.6%$46.08MN/A-18.0443Positive NewsShort Interest ↑High Trading VolumeRNXTRenovoRx2.3268 of 5 stars$1.25-1.6%$7.25+480.0%-1.6%$45.71M$40K-3.136Analyst DowngradeXCURExicure0.777 of 5 stars$7.22-8.0%N/A+1,324.5%$45.63M$500K-1.8950News CoverageShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ACRVAcrivon Therapeutics2.7568 of 5 stars$1.43flat$17.71+1,138.8%-83.9%$44.83MN/A-0.6458CGTXCognition Therapeutics2.114 of 5 stars$0.72-14.9%$2.83+296.2%-25.8%$44.33MN/A-0.9720Upcoming EarningsShort Interest ↑Gap DownLTRNLantern Pharma2.2777 of 5 stars$4.01-5.4%$25.00+523.4%+17.5%$43.23MN/A-2.1820News CoverageUpcoming EarningsShort Interest ↑Gap DownELYMEliem TherapeuticsN/A$1.45-2.0%N/A-80.9%$43.14MN/A-2.749 Related Companies and Tools Related Companies PEPG Competitors JSPR Competitors CVM Competitors RNXT Competitors XCUR Competitors NBRV Competitors ACRV Competitors CGTX Competitors LTRN Competitors ELYM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
